VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine

28 Jun 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

27 Jun 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies Healthcare Conference

24 May 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

09 May 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

02 May 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update

25 Apr 2023 01:00:00 By Nasdaq GlobeNewswire

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

10 Apr 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

07 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

21 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

20 Dec 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD

19 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

09 Nov 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces November 2022 Investor Conference Participation

02 Nov 2022 02:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update

26 Oct 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

17 Oct 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD

14 Oct 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

29 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma strengthens commercialization leadership team

24 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

19 Aug 2022 01:46:07 By Nasdaq GlobeNewswire

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

15 Aug 2022 15:05:00 By Nasdaq GlobeNewswire